Newsfiscal.ai
Arvinas to Present Preliminary Phase 1 Data for ARV-393 at 2026 ASH Annual Meeting
· Published
Article summary
Arvinas announced that preliminary clinical data from its Phase 1 study of ARV-393 (zaloblideg) for relapsed/refractory non-Hodgkin lymphoma will be presented at the 2026 ASH Annual Meeting.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…